CLINICAL USE

Aid to smoking cessation

DOSE IN NORMAL RENAL FUNCTION

0.5 mg once daily for 3 days, 0.5 mg twice daily for 3 days, then 0.5–1 mg twice daily

PHARMACOKINETICS

  • Molecular weight                           : 361.3 (as tartrate)
  • %Protein binding                           : <20
  • %Excreted unchanged in urine     : 92
  • Volume of distribution (L/kg)       : 415 litres
  • half-life – normal/ESRD (hrs)      : 24/Increased

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

    Initial doses as for normal renal function, then maintenance doses of: 30–50 1 mg once or twice daily 10–30 1 mg once daily

  • <10           : 0.5–1 mg once daily

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                : Unknown dialysability. Dose as in GFR <10 mL/min
  • HD                     : Dialysed. Dose as in GFR <10 mL/min
  • HDF/high flux   : Dialysed. Dose as in GFR <10 mL/min
  • CAV/VVHD      : Dialysed. Dose as in GFR=10–30 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • None known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    – .

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia